20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Alvotech (ALVO) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Luxembourg, Luxembourg with about 1,279 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, ALVO reported $586M in revenue and $28M in net income.
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Interactive charts & full statements → Open the ALVO valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $492M | $586M | $490M | $91M | $83M | $37M | $67M | $32M |
| Gross Profit | $298M | $351M | $304M | ($69M) | $19M | $37M | $67M | $32M |
| Gross Margin % | 60.6% | 59.8% | 62.2% | -75.9% | 22.8% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | $47M | $78M | $70M | ($355M) | ($346M) | ($235M) | ($138M) | ($61M) |
| Operating Margin % | 9.6% | 13.3% | 14.2% | -388.1% | -417.3% | -640.3% | -206.5% | -192.5% |
| Net Income | ($180M) | $28M | ($232M) | ($552M) | ($514M) | ($102M) | ($170M) | ($210M) |
| Net Margin % | -36.6% | 4.8% | -47.3% | -603.4% | -618.6% | -276.0% | -255.3% | -657.5% |
| EBITDA | ($2M) | $323M | ($32M) | ($494M) | ($440M) | ($18M) | ($178M) | ($99M) |
| Earnings Per Share (EPS) | $-0.60 | $0.10 | $-0.87 | $-2.43 | $-2.60 | $-3.25 | $-0.70 | $-0.86 |
| Shares Outstanding (M) | 357M | 279M | 268M | 227M | 198M | 31M | — | 244M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $106M | $106M | $166M | $114M | $173M | $133M | $151M | $103M |
| Gross Profit | $54M | $60M | $105M | $79M | $99M | $67M | $71M | $63M |
| Gross Margin % | 50.6% | 56.5% | 63.2% | 69.3% | 57.4% | 50.7% | 46.9% | 61.3% |
| Operating Income (EBIT) | ($12M) | $10M | $48M | $1M | $18M | $11M | $13M | $13M |
| Operating Margin % | -11.2% | 9.1% | 29.0% | 1.2% | 10.4% | 8.0% | 8.9% | 12.4% |
| Net Income | ($67M) | $1M | ($109M) | ($5M) | $32M | $110M | ($67M) | ($11M) |
| Net Margin % | -63.2% | 1.0% | -65.3% | -4.6% | 18.5% | 82.6% | -44.3% | -11.1% |
| EBITDA | ($2M) | $52M | ($85M) | $33M | $52M | $137M | ($120M) | $138M |
| Earnings Per Share (EPS) | $-0.19 | $0.00 | $-0.39 | $-0.02 | $0.10 | $0.35 | $-0.22 | $-0.04 |
| Shares Outstanding (M) | 357M | 330M | 279M | 300M | 313M | 313M | 302M | 280M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($199M) | ($50M) | ($237M) | ($312M) | ($312M) | ($228M) | ($74M) | ($89M) |
| Capital Expenditures (CapEx) | $102M | $64M | $57M | $46M | $49M | $41M | $12M | $8M |
| Free Cash Flow (FCF) | ($301M) | ($115M) | ($294M) | ($359M) | ($361M) | ($269M) | ($86M) | ($97M) |
| FCF Margin % | -61.2% | -19.6% | -60.0% | -392.3% | -435.3% | -731.0% | -129.5% | -302.6% |
| Dividends Paid | — | — | — | — | $185M | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($20M) | ($60M) | ($63M) | ($56M) | $56M | $13M | ($39M) | ($72M) |
| Capital Expenditures (CapEx) | $28M | $46M | $9M | $19M | $14M | $23M | $31M | $14M |
| Free Cash Flow (FCF) | ($48M) | ($107M) | ($71M) | ($75M) | $42M | ($11M) | ($70M) | ($85M) |
| FCF Margin % | -45.1% | -100.7% | -43.0% | -65.4% | 24.3% | -8.2% | -46.5% | -83.1% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|
| Total Assets | $1.6B | $1.5B | $1.2B | $950M | $828M | $598M | $474M |
| Cash & Cash Equivalents | $143M | $172M | $51M | $11M | $66M | $18M | $32M |
| Total Liabilities | $1.8B | $1.8B | $1.6B | $1.9B | $1.4B | $734M | $1.3B |
| Total Debt (Short + Long-Term) | $1.3B | $1.3B | $1.1B | $970M | $770M | $408M | $573M |
| Total Shareholders' Equity | ($191M) | ($284M) | ($413M) | ($932M) | ($564M) | ($136M) | ($867M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ALVO viewer.
About TickerBase · Data methodology & sources · Privacy · Terms